Carisma Therapeutics (CARM) News Today $0.46 +0.00 (+0.06%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.47 +0.00 (+0.65%) As of 02/21/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 19 at 7:30 AM | prnewswire.comCarisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | prnewswire.comCARISMA Therapeutics (NASDAQ:CARM) Stock, Short Interest ReportJanuary 31, 2025 | benzinga.comCARISMA Therapeutics (NASDAQ:CARM) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comCarisma Therapeutics (CARM) Receives a Hold from BTIGJanuary 16, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Carisma Therapeutics (CARM)December 17, 2024 | msn.comCarisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline ReprioritizationDecember 15, 2024 | msn.comCarisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline ProspectsDecember 12, 2024 | markets.businessinsider.comCarisma Therapeutics (CARM) was downgraded to a Hold Rating at BTIGDecember 12, 2024 | markets.businessinsider.comBaird Downgrades Carisma Therapeutics (CARM)December 12, 2024 | msn.comCarisma downgraded by Baird over lack of near-term catalystsDecember 12, 2024 | msn.comEvercore ISI Group Downgrades Carisma Therapeutics (CARM)December 12, 2024 | msn.comCarisma Therapeutics downgraded to In Line from Outperform at Evercore ISIDecember 11, 2024 | markets.businessinsider.comBTIG downgrades Carisma Therapeutics (CARM) to a HoldDecember 10, 2024 | markets.businessinsider.comCarisma Therapeutics price target lowered to $12 from $24 at D. Boral CapitalDecember 10, 2024 | markets.businessinsider.comCarisma Therapeutics Restructures Amid Strategic RefocusDecember 9, 2024 | markets.businessinsider.comCarisma Therapeutics Announces Strategic Reprioritization Of Pipeline; To Cut Workforce By 34%December 9, 2024 | markets.businessinsider.comPenn spinout Carisma Therapeutics to narrow R&D focus, lay off more than a third of its workforceDecember 9, 2024 | bizjournals.comCarisma Therapeutics Announces Strategic Restructuring to Re-prioritize PipelineDecember 9, 2024 | prnewswire.comCarisma Therapeutics CEO to Speak at 7th Annual Evercore ISI HealthCONx ConferenceDecember 3, 2024 | msn.comCarisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 27, 2024 | prnewswire.comCarisma Therapeutics, Inc. (CARM)November 20, 2024 | finance.yahoo.comCarisma Reports Promising Preclinical Data On Engineered Macrophages For Liver FibrosisNovember 18, 2024 | markets.businessinsider.comCarisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024November 17, 2024 | prnewswire.comOptimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial StandingNovember 12, 2024 | markets.businessinsider.comCarisma Therapeutics Reports Q3 2024 Results, Advances Clinical ProgramsNovember 12, 2024 | msn.comEvercore ISI Remains a Buy on Carisma Therapeutics (CARM)November 10, 2024 | markets.businessinsider.comCarisma Therapeutics reports data from its CAR-M therapyNovember 8, 2024 | markets.businessinsider.comCarisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular CarcinomaNovember 8, 2024 | prnewswire.comCarisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | prnewswire.comCarisma to present new data on CAR-M therapy for hepatocellular carcinomaNovember 5, 2024 | markets.businessinsider.comCarisma Therapeutics Welcomes Sohanya Cheng to Board of DirectorsNovember 5, 2024 | msn.comCarisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024November 5, 2024 | prnewswire.comLeadership Transition at Carisma Therapeutics’ Board of DirectorsNovember 1, 2024 | markets.businessinsider.comEF Hutton Initiates Coverage of Carisma Therapeutics (CARM) with Buy RecommendationNovember 1, 2024 | msn.comCarisma Therapeutics Announces Changes to its Board of DirectorsOctober 30, 2024 | prnewswire.comCarisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024October 8, 2024 | msn.comCarisma Therapeutics Announces Upcoming Presentations at SITC 2024October 4, 2024 | prnewswire.comCarisma, Moderna To Expand Collaboration; Moderna Nominates Two Autoimmune Disease TargetsSeptember 11, 2024 | markets.businessinsider.comCarisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune DiseasesSeptember 10, 2024 | prnewswire.comCarisma Therapeutics CEO to Present at Key Industry ConferencesSeptember 9, 2024 | msn.comCarisma Therapeutics to Present at Upcoming ConferencesSeptember 3, 2024 | prnewswire.comCarisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis TreatmentAugust 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)August 9, 2024 | markets.businessinsider.comCarisma Therapeutics Inc.: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 9, 2024 | finanznachrichten.deCarisma Therapeutics GAAP EPS of -$0.27 beats by $0.03, revenue of $9.2M beats by $5.28MAugust 9, 2024 | msn.comCarisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | prnewswire.comCarisma Therapeutics Announces Expansion of Its Scientific Advisory BoardAugust 6, 2024 | prnewswire.comCarisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024August 6, 2024 | prnewswire.comCan Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?August 3, 2024 | finance.yahoo.com Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address CARM Media Mentions By Week CARM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CARM News Sentiment▼0.000.60▲Average Medical News Sentiment CARM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CARM Articles This Week▼11▲CARM Articles Average Week Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Clearside Biomedical News Theratechnologies News Assertio News Genenta Science News PyroGenesis Canada News I-Mab News Pyxis Oncology News Adagene News Karyopharm Therapeutics News ZIVO Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CARM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts